Navigation Links
Ovarian cancer cells bully their way through tissue
Date:6/14/2011

BOSTON, Mass. (June 14, 2011) A team led by Joan Brugge, the Louise Foote Pfeiffer Professor of Cell Biology at Harvard Medical School, recently shed light on how ovarian cancer spreads. In a paper published in the July edition of the journal Cancer Discovery, the newest journal of the American Association for Cancer Research, Brugge and colleagues found that ovarian cancer cells act like bullies, using brute force to plow their way through tissue and colonize additional organs.

"This is the first time that mechanical force has been implicated in the spread of ovarian cancer," says Brugge, who is also chair of the Department of Cell Biology. "While this research is still preliminary, we are building a foundation for the development of treatments based on a robust understanding of the disease."

According to the National Cancer Institute, ovarian cancer accounts for about three percent of all cancers among women in the United States. It caused nearly 14,000 deaths in 2010 alone.

The ovaries and many other organs, such as the liver, stomach and intestines, are located in an anatomical space called the peritoneal cavity. The lining of this cavity is called the peritoneum, and its top layer is called the mesothelium. After an ovarian tumor develops, clusters of cancer cells are released into the peritoneal cavity. Each cluster floats around until it encounters the lining of the cavity. It attaches to the lining, spreads out and launches an invasion into the mesothelium. Brugge's team determined how ovarian cancer cells get through the mesothelium to colonize organs on the other side.

When researchers placed ovarian cancer cells and mesothelial cells together in a dish, the cancer cells formed a hole in the mesothelial layer, mirroring behavior that would occur in the body as an invasion proceeds. The team interfered with molecular components of the cancer cells one by one and used time-lapse microscopy to watch the result. If the hole failed to form, the researchers knew that they'd discovered a critical player in the invasion process.

They identified three such playersintegrin, talin and myosin, which are all proteins known to play a role in cell movement. Integrin sticks out from the cancer cells and grabs hold of scaffolding surrounding the mesothelium. Myosin, which is a motor, pulls on integrin via talin. As a result, the protruding cancer cells gain traction and can now force mesothelial cells out of the way.

"The cancer cells act like bullies," says first author Marcin Iwanicki, a postdoctoral researcher in Brugge's lab. "Instead of relying on a sophisticated biochemical process to achieve their goal, they simply push mesothelial cells apart."

"Eventually, it might be possible to prevent or reverse the invasion process," says Brugge. "We hope that our work will inform such treatments in the future."


'/>"/>

Contact: David Cameron
communications@hms.harvard.edu
617-432-0442
Harvard Medical School
Source:Eurekalert

Related medicine news :

1. Hormone test predicts ovarian function after chemotherapy for breast cancer
2. Cancer Drug Avastin Makes Inroads Against Ovarian Tumors
3. Ovarian cancer screening does not appear to reduce risk of ovarian cancer death
4. Targeted testing offers treatment hope for ovarian cancer patients
5. Study Finds Ovarian Screening Tests Dont Improve Survival
6. Motor protein may offer promise in ovarian cancer treatment
7. New scientific model tracks form of ovarian cancer to origins in fallopian tube
8. Ovarian cancer finding may be a win-win for at-risk women who wish to have a family
9. Ovarian Cancer Prognosis May Depend on Gene Mutations
10. Philanthropic pledge triples funds for TGen ovarian cancer research
11. Ohio State study: Targeted ovarian cancer therapy not cost-effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... ... 25, 2017 , ... Bellus Medical, a leader in medical ... new class of photodynamic cosmetics (PDC). , Allumera® is the first PDC cream ... of aging, and minimize the appearance of pores – all with minimal downtime ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... they have signed an agreement to be the preferred physical therapy provider for ... and returning them to Derby City CrossFit as quickly and effectively as possible, ...
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment ... can also decrease overall productivity and performance in the workplace. The goal of Clearview ... the last few weeks of April, Clearview Resolution Services will be shutting down the ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  New research provides evidence that an old drug ... a study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... Parkinson,s disease, the oral drug levodopa has long been considered ... as the disease progresses, the effects of the medication can ...
(Date:4/19/2017)... THOUSAND OAKS, Calif. , April 19, 2017 ... premium industrial buildings it is developing at Conejo ... California , to Atara Biotherapeutics, Inc. ... patients with severe and life-threatening diseases that have ... focus on allogeneic T-cell therapies for cancer, autoimmune ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
Breaking Medicine Technology: